Suvretta Capital Management LLC Invests $1.12 Million in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Suvretta Capital Management LLC acquired a new position in Centessa Pharmaceuticals plc (NASDAQ:CNTA) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 70,000 shares of the company’s stock, valued at approximately $1,119,000.

A number of other institutional investors and hedge funds have also bought and sold shares of CNTA. First Light Asset Management LLC boosted its holdings in Centessa Pharmaceuticals by 59.2% in the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after purchasing an additional 1,778,515 shares during the period. Farallon Capital Management LLC lifted its stake in shares of Centessa Pharmaceuticals by 438.0% in the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock valued at $18,024,000 after buying an additional 1,625,000 shares during the period. Driehaus Capital Management LLC lifted its stake in shares of Centessa Pharmaceuticals by 89.5% in the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock valued at $18,891,000 after buying an additional 987,997 shares during the period. Perceptive Advisors LLC grew its position in Centessa Pharmaceuticals by 27.6% during the second quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock worth $35,518,000 after buying an additional 850,000 shares in the last quarter. Finally, Nantahala Capital Management LLC bought a new position in Centessa Pharmaceuticals during the second quarter valued at about $4,064,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Up 1.7 %

Shares of NASDAQ CNTA opened at $17.60 on Friday. Centessa Pharmaceuticals plc has a 52-week low of $5.58 and a 52-week high of $18.74. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The business has a fifty day moving average of $16.16 and a two-hundred day moving average of $12.57. The stock has a market cap of $2.32 billion, a PE ratio of -11.50 and a beta of 1.47.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. As a group, equities research analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on CNTA. Oppenheimer reiterated an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. BMO Capital Markets raised their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, September 16th. Guggenheim boosted their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. Jefferies Financial Group raised their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Finally, Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $25.83.

Insider Activity

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 16,619 shares of the stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $15.69, for a total transaction of $260,752.11. Following the sale, the insider now owns 206,750 shares of the company’s stock, valued at $3,243,907.50. This represents a 7.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Saurabh Saha sold 1,671 shares of the business’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $18.24, for a total transaction of $30,479.04. Following the completion of the transaction, the chief executive officer now directly owns 575,661 shares of the company’s stock, valued at approximately $10,500,056.64. This represents a 0.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 375,128 shares of company stock worth $6,148,522. Insiders own 11.59% of the company’s stock.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.